Application Note

In Vitro Glycoengineering – Suitability For BioPharma Manufacturing

Source: Roche CustomBiotech

By Sebastian Malik, Marco Thomann, Pharma Technical Development Penzberg; Roche Diagnostics GmbH; Penzberg, Germany

getty- 1299289706 -immunoglobulin-proteins

The importance of Fc glycosylation of mAbs with regard to biological activity is widely discussed and has been investigated in numerous studies. It is known that different glycan species contribute differently to the biological activity of therapeutic proteins. However, even if a certain glycan variant is known to have a positive impact on biological activity, it might not be easy to consistently produce such a glycosylation pattern. Cell line engineering or bioprocess optimization can enable increased glycosylation homogeneity or at least partially achieve a certain glycan pattern. However, these activities are time-consuming and might compromise other key parameters, such as antibody yield. In addition, it is not economical to produce mAbs with a certain glycan pattern in analytical amounts using such tedious approaches. This problem can now be solved using in vitro glycoengineering (IVGE).

In this assessment of the in vitro glycoengineering technology we determine is it is suitable for the development, manufacturing, and analysis of therapeutic proteins. The assessment was conducted by considering enzyme activity, implementation into the manufacturing process, enzyme versatility and growth in scale and quality during drug development.

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Med Device Online? Subscribe today.

Subscribe to Med Device Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Med Device Online